Research
KPV in skin research
KPV studied in keratinocytes, reconstructed skin and excised human skin, including permeation data FDA cited and early mouse irritation models.
By the KPV Peptide editorial team · Last reviewed · Editorial review: approved by Ryan DeLauz (bulk sign-off in chat, 2026-11-11)
Short answer
KPV skin research covers keratinocyte cultures, reconstructed skin, permeation through excised human skin, and mouse irritation models. No study has applied KPV to the skin of human volunteers [FDA briefing 2026]. The proposed compounded products FDA reviewed in 2026 were topical creams and gels.
Can KPV get through skin?
On dermatomed human skin, passive permeation was below the 0.01 µg/mL detection limit. Microneedle pre-treatment raised flux to 4.4 µg/cm²/h, and iontophoresis combined with microneedles raised it a further 35-fold [Pawar 2017]. The same group validated an HPLC method that can measure KPV in skin homogenate[Pawar 2015]. FDA cited the permeation result as a reason topical effectiveness and systemic exposure are both uncertain [FDA briefing 2026].
Keratinocyte studies
In HaCaT keratinocytes and a 3D skin model exposed to particulate matter, KPV-treated cultures had higher viability and lower ROS, caspase-1 and IL-1β [Sung 2025]. Earlier work found KPV did not raise cAMP in keratinocytes [Elliott 2004] and inhibited peroxide-stimulated glutathione peroxidase activity at higher concentrations than α-MSH [Haycock 2000].
Animal models
Mouse studies measured smaller irritant-induced ear swelling [Hiltz 1989], with D-amino-acid analogues varying in activity [Hiltz 1991]. In rabbits, topical KPV was associated with faster corneal re-epithelialisation [Bonfiglio 2006].
Studies in this area
| Study | Model | What was measured | Limitations | Grade |
|---|---|---|---|---|
| Hiltz 1989 FASEB J Skin and keratinocyte models · Systemic inflammation and fever models | Animal Mouse (picryl chloride ear swelling) | Measured irritant-induced ear swelling in mice; the tripeptide reduced swelling in a dose-related fashion. | Single irritant model; sample size not in abstract. | Evidence grade C |
| Hiltz 1990 Peptides Skin and keratinocyte models · Systemic inflammation and fever models | Animal Mouse (paw edema; contact sensitivity) | Measured paw edema and contact-sensitivity responses in mice; MSH peptides including the tripeptide reduced both. | Abstract does not separate tripeptide results from the full hormone in detail. | Evidence grade C |
| Hiltz 1991 Peptides Skin and keratinocyte models | Animal Mouse (picryl chloride ear swelling) | Compared stereochemical analogues; L-Pro12 was required for activity and D-Val13 substitution increased activity about four-fold over the parent tripeptide. | Analogues, not native KPV; bell-shaped dose-response complicates interpretation. | Evidence grade C |
| Haycock 2000 J Biol Chem Skin and keratinocyte models | In vitro Human HaCaT keratinocytes and HBL melanoma cells | Measured glutathione peroxidase activity and intracellular peroxide; MSH 11-13 inhibited the stimulated activity at 10-100-fold higher concentrations than alpha-MSH. | Cell lines; biphasic dose-response. | Evidence grade D |
| Elliott 2004 J Invest Dermatol Skin and keratinocyte models | In vitro Human HaCaT and normal human keratinocytes | Measured cAMP and intracellular calcium; no cAMP rise was detected, while rapid calcium responses occurred only when the cAMP pathway was inhibited. | Signalling readouts only; no inflammatory endpoint. | Evidence grade D |
| Bonfiglio 2006 Exp Eye Res Tissue-repair models | Animal Rabbit corneal epithelial abrasion; rabbit corneal epithelial cells | Measured corneal re-epithelialisation; 8 of 8 KPV-treated corneas were re-epithelialised at 60 h vs none of the controls, and an NOS inhibitor blocked the effect. | Small animal sample; single tissue model. | Evidence grade C |
| Pawar 2017 J Pharm Sci Skin and keratinocyte models · Delivery and formulation | Ex vivo Dermatomed human skin (in vitro permeation) | Measured transdermal permeation; passive permeation was below the 0.01 ug/mL detection limit, microneedles gave 4.4 ug/cm2/h, and iontophoresis plus microneedles gave 35-fold more than microneedles alone. | Excised skin; no biological endpoint. | Evidence grade D |
| Shao 2021 Biomater Sci Tissue-repair models · Antimicrobial assays · Delivery and formulation | Animal Rat chemotherapy-induced oral mucositis; MRSA-infected gingival wounds | Measured food intake, body weight, gingival histology, CK10/PCNA, IL-1 beta, TNF-alpha and IL-10 in rats treated with the KPV-loaded hydrogel. | Carrier contains EGCG, which is itself antibacterial; effects are of the combination. | Evidence grade C |
| Sung 2025 Tissue Cell Skin and keratinocyte models | In vitro Human HaCaT keratinocytes and 3D skin model exposed to PM10 | Measured viability, ROS, ERK/p38 activation, apoptosis proteins, caspase-1 and IL-1 beta after PM10 exposure; KPV-treated cultures showed lower ROS and IL-1 beta and higher viability. | Cell line and reconstructed tissue only. | Evidence grade D |
References
- Pawar K, Kolli CS, Rangari VK et al. (2017). Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. J Pharm Sci. PubMed 28343991 · doi:10.1016/j.xphs.2017.03.017[Ex vivo, grade D]
- Pawar KR, Mulabagal V, Smith F et al. (2015). Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatogr. PubMed 25298219 · doi:10.1002/bmc.3347[Analytical, grade D]
- Sung J, Ju SY, Park S et al. (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell. PubMed 40073467 · doi:10.1016/j.tice.2025.102837[In vitro, grade D]
- Elliott RJ, Szabo M, Wagner MJ et al. (2004). alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. PubMed 15102092 · doi:10.1111/j.0022-202X.2004.22404.x[In vitro, grade D]
- Haycock JW, Rowe SJ, Cartledge S et al. (2000). Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines. J Biol Chem. PubMed 10821844 · doi:10.1074/jbc.275.21.15629[In vitro, grade D]
- Hiltz ME, Lipton JM (1989). Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. PubMed 2550304[Animal, grade C]
- Hiltz ME, Catania A, Lipton JM (1991). Anti-inflammatory activity of alpha-MSH(11-13) analogs: influences of alteration in stereochemistry. Peptides. PubMed 1788140 · doi:10.1016/0196-9781(91)90131-8[Animal, grade C]
- Bonfiglio V, Camillieri G, Avitabile T et al. (2006). Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. PubMed 16965771 · doi:10.1016/j.exer.2006.07.014[Animal, grade C]
- U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee (2026-07-23). FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate). Source[retrieved 2026-11-11]